title: L-DOPA and graft-induced dyskinesia: different treatment, same story?
abstract: One of the well-recognized problems of long-term L-3,4-dihydroxyphenylalanine (L-DOPA) therapy in the treatment of Parkinson's disease is the development of L-DOPA induced dyskinesia. These abnormal movements cause significant disability and narrow the therapeutic window of L-DOPA. Cell transplantation is one of the most promising upcoming therapies for the treatment of Parkinson's disease, and may help alleviate or avoid L-DOPA-induced dyskinesia. However, the more recently acknowledged phenomenon of graft-induced dyskinesia is posing a major obstacle to the success of this treatment. This motor side-effect closely resembles abnormal movements induced by chronic L-DOPA treatment, yet they remain after withdrawal of the medication indicating their origins lie in the transplant. In this review, we compare these two therapy-induced adverse effects, from the way they manifest in patients to the possible mechanisms underlying their development.
authors.affiliation: School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, CF10 3NB, UK.
authors.forename: Ludivine S
authors.initials: LS
authors.lastname: Breger
authors.forename: Emma L
authors.initials: EL
authors.lastname: Lane
mesh_terms: D000818:Animals; D017690:Cell Transplantation / Q000009:adverse effects*; D004195:Disease Models, Animal; D020820:Dyskinesias / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*
chemical_list: D007980:Levodopa
keywords: 5-HT; Parkinson’s disease; animal model; transplantation